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AML, there have been sparse reports regarding the outcome
of cord blood transplantation (CBT) for the population.
Patients and methods: We retrospectively reviewed
patients diagnosed as primary refractory AML who under-
went CBT at our institute from Mar. 2003 to June 2013
consecutively.
Results: Seventy-seven patients were included in this study.
Underlying diseases were de novo AML in 50 (65%) and AML-
MRC in 27 (35%). Forty-nine (61%) were male and 30 (39%)
were female. Their median age was 59 years (range 19-72).
The number of prior chemotherapy was 1 course in 28 (36%),
2 in 30 (39%), and more than 3 in 19 (25%), respectively.
Median time from diagnosis to transplantation was 162 days
(range; 64-1539). TBI+Cy/Bu+Cy was used as pretransplant
conditioning regimen in 4 patients, Flu+Mel80+TBI4 in 23,
Flu+Bu16+Mel80 in 26, Flu+Bu16+TBI2-4 in 12, and other RIC
regimens in 12. Nineteen patients died before engraftment.
Among the remaining 58 patients, 42 achieved neutrophil
engraftment with a median of 21 days post-transplant
(range; 13-45). Nine patients received urgent 2nd CBT for
primary graft failure (n¼6) or early disease relapse (n¼3).
Among the 42 evaluable patients, 36 (86%) developed acute
GVHD of grade II or higher, including 11 (26%) patients who
developed that of grade III or IV. Of the 36 patients who
survived longer than 100 days post-transplant, 21 patients
developed chronic GVHD, including 13 with limited and 8
with extensive form. With a median observation time for
survivors of 16.5 months (range; 3-94), 2 year overall sur-
vival (OS) and disease free survival (DFS) were 31.4% and
22.4%, respectively. Cumulative incidences of relapse and
non-relapse mortality (NRM) at 2 years post-transplant were
35% and 42.2%, respectively. In univariate analysis, patients
with aged 19-60 showed superior OS at 2 years compared to
elderly patients (>61 years) (44.8% vs 16.4% p¼0.013).
Relapse rate was signiﬁcantly higher in the elderly compared
to those with aged 19-60 (50.5% vs 21.7%, P<0.01), whereas
NRM did not differ between the two groups (43.3% vs 40.2%,
P¼0.87). Eighteen patients died of disease relapse and 36
died of NRM, including graft failure (3), infection (20),
bleeding (2), organ failure (4), TMA (3) and idiopathic
pneumonia syndrome (4).
Conclusion: Our results suggested that CBT is a feasible and
promising treatment approach for patients with primary
refractory AML. Optimal strategies for decreasing relapse
especially in the elderly should be established to improve the
outcome.219
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Introduction: Cytogenetic changes that accompany the
relapse of myeloid neoplasms after allogeneic hematopoietic
cell transplantation (HCT) have not been well studied. The
goal of our study is to evaluate the frequency and spectrum
of the cytogenetic change that occurs at relapse of myeloid
malignancies after HCT and evaluate the impact on
prognosis.
Methods: We performed a retrospective review of all pa-
tients who relapsed following an allogeneic HCT for a
myeloid malignancy. Cytogenetic ﬁndings at diagnosis and atrelapse were compared. Cytogenetic studies were performed
according to conventional methods.
Results: Of 212 patients transplanted for a myeloid malig-
nancy between 03/2004-01/2013, 43 relapsed (34AML,
1CML, 4MDS and 4MPN) at a median time of 113 days (range
22-820 days). Cytogenetic ﬁndings at relapse were different
from diagnosis in 14/43 patients (32.5%). The mean number
of cytogenetic alterations/patient increased from 1.09 at
diagnosis to 1.51 at relapse. The majority (10/14) represented
clonal evolution deﬁned as acquisition of more complex
abnormalities. This group includes 3 patients with normal
karyotype at diagnosis and 7 patients who originally showed
one, two, or complex abnormalities. All of these 10 patients
developed complex abnormalities (deﬁned as >3 abnor-
malities). Other than clonal evolution, new-onset chromo-
somal abnormalities unrelated to diagnosis were seen in
three patients, two of which acquired a more favorable
cytogenetic proﬁle than at diagnosis (inverted chromosome
16 and a single abnormality in a patient with complex
karyotype at diagnosis, respectively). One patient with
normal karyotype AML acquired a donor-derived del(20q)
abnormality.
Conclusions: Cytogenetic change is common at relapse of
myeloid neoplasms after HCT and is associated with an
increasing cytogenetic complexity. The acquisition of more
unfavorable cytogenetic proﬁles likely contributes to poor
outcomes. Exceptions to this trend are patients that acquire
more favorable cytogenetic features than at diagnosis,
resulting in potentially better response to therapy and longer
survival. The signiﬁcance of donor-cell-derived del(20q), a
rare recurrent cytogenetic abnormality in the post-trans-
plant setting, is not clear.220
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